Low-sensitivity FDG-PET studies: Less common lung neoplasms

Seminars in Nuclear Medicine

Volumn 42, Issue 4, 2012, Pages 255-260

  Erasmus, Jeremy J ^a   MacApinlac, Homer A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 3' FLUOROTHYMIDINE F 18; 6 FLUORODOPA F 18; ARGINYLGLYCYLASPARTIC ACID; COPPER DIACETYLBIS(N4 ETHYLTHIOSEMICARBAZONE); DOTANOC GA 68; DOTATATE GA 68; FLUCICLATIDE F 18; FLUORODEOXYGLUCOSE F 18; SUNITINIB; TETRAXETAN; THIOSEMICARBAZONE DERIVATIVE; TRACER; UNCLASSIFIED DRUG;

CANCER DIAGNOSIS; CANCER STAGING; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DRUG RESPONSE; DRUG UPTAKE; HUMAN; IMAGE ANALYSIS; LUNG CANCER; LUNG NODULE; NONHUMAN; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; REVIEW;

ANIMALS; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOACTIVE TRACERS; SENSITIVITY AND SPECIFICITY;

EID: 84861996778     PISSN: 00012998     EISSN: 15584623     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2012.03.001     Document Type: Review

References (33)

1. Yap CS, Schiepers C, Fishbein MC, et al: FDG-PET imaging in lung cancer: How sensitive is it for bronchioloalveolar carcinoma?. Eur J Nucl Med Mol Imaging 2002;29:1166-1173 (Pubitemid 34985361)
2. Wahbah M, Boroumand N, Castro C, et al: Changing trends in the distribution of the histologic types of lung cancer: A review of 4,439 cases. Ann Diagn Pathol 2007;11:89-96 (Pubitemid 46350914)
3. Travis WD, Brambilla E, Noguchi M, et al: International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011;6:244-285
4. Noguchi M, Morikawa A, Kawasaki M, et al: Small adenocarcinoma of the lung: histologic characteristics and prognosis. Cancer 1995;75:2844-2852
5. Yang ZG, Sone S, Takashima S, et al: High-resolution CT analysis of small peripheral lung adenocarcinomas revealed on screening helical CT. Am J Roentgenol 2001;176:1399-1407 (Pubitemid 32510250)
6. Takashima S, Li F, Maruyama Y, et al: Discrimination of subtypes of small adenocarcinoma in the lung with thin-section CT. Lung Cancer 2002;36:175-182 (Pubitemid 34296559)
7. Kishi K, Homma S, Kurosaki A, et al: Small lung tumors with the size of 1cm or less in diameter: Clinical, radiological, and histopathological characteristics. Lung Cancer 2004;44:43-51 (Pubitemid 38317261)
8. Lee HY, Lee KS: Ground-glass opacity nodules: Histopathology, imaging evaluation, and clinical implications. J Thorac Imaging 2011;26:106-118
9. Nakata M, Sawada S, Saeki H, et al: Prospective study of thoracoscopic limited resection for ground-glass opacity selected by computed tomography. Ann Thorac Surg 2003;75:1601-1605; discussion 1605-1606
10. Hasegawa M, Sone S, Takashima S, et al: Growth rate of small lung cancers detected on mass CT screening. Br J Radiol 2000;73:1252-1259 (Pubitemid 32123826)
11. Godoy MC, Naidich DP: Subsolid pulmonary nodules and the spectrum of peripheral adenocarcinomas of the lung: Recommended interim guidelines for assessment and management. Radiology 2009;253:606-622
12. Min JH, Lee HY, Lee KS, et al: Stepwise evolution from a focal pure pulmonary ground-glass opacity nodule into an invasive lung adenocarcinoma: An observation for more than 10 years. Lung Cancer 2010;69:123-126
13. Gould MK, Maclean CC, Kuschner WG, et al: Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: A meta-analysis. JAMA 2001;285:914-924 (Pubitemid 32171553)
14. Yi CA, Lee KS, Kim BT, et al: Tissue characterization of solitary pulmonary nodule: Comparative study between helical dynamic CT and integrated PET/CT. J Nucl Med 2006;47:443-450 (Pubitemid 46768487)
15. Bryant AS, Cerfolio RJ: The maximum standardized uptake value on integrated FDG-PET/CT is useful in differentiating benign from malignant pulmonary nodules. Ann Thorac Surg 2006;82:1016-1020
16. Nomori H, Watanabe K, Ohtsuka T, et al: Evaluation of F-18 fluorodeoxyglucose (FDG) PET scanning for pulmonary nodules less than 3 cm in diameter, with special reference to the CT images. Lung Cancer 2004;45:19-27 (Pubitemid 38757828)
17. Chi PC, Mawlawi O, Luo D, et al: Effects of respiration-averaged computed tomography on positron emission tomography/computed tomography quantification and its potential impact on gross tumor volume delineation. Int J Radiat Oncol Biol Phys 2008;71:890-899 (Pubitemid 351749538)
18. Vaupel P, Harrison L: Tumor hypoxia: Causative factors, compensatory mechanisms, and cellular response. Oncologist 2004;9(suppl 5):4-9 (Pubitemid 39658340)
19. Overgaard J, Horsman MR: Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol 1996;6:10-21 (Pubitemid 26029371)
20. Koh WJ, Rasey JS, Evans ML, et al: Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int J Radiat Oncol Biol Phys 1992;22:199-212
21. Cherk MH, Foo SS, Poon AM, et al: Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F-fluoromisonidazole and 18F-FDG-PET. J Nucl Med 2006;47:1921-1926 (Pubitemid 47544979)
22. Fujibayashi Y, Taniuchi H, Yonekura Y, et al: Copper-62-ATSM: A new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med 1997;38:1155-1160 (Pubitemid 27339632)
23. Dehdashti F, Mintun MA, Lewis JS, et al: In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging 2003;30:844-850 (Pubitemid 36734203)
24. Lewis JS, Laforest R, Dehdashti F, et al: An imaging comparison of 64Cu-ATSM and 60Cu-ATSM in cancer of the uterine cervix. J Nucl Med 2008;49:1177-1182 (Pubitemid 351948028)
25. Everitt S, Hicks RJ, Ball D, et al: Imaging cellular proliferation during chemo-radiotherapy: A pilot study of serial 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2009;75:1098-1104
26. Sohn HJ, Yang YJ, Ryu JS, et al: [18F]fluorothymidine positron emission tomography before and 7 days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung. Clin Cancer Res 2008;14:7423-7429
27. Kenny L, Coombes RC, Vigushin DM, et al: Imaging early changes in proliferation at 1 week post chemotherapy: A pilot study in breast cancer patients with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging 2007;34:1339-1347 (Pubitemid 47312585)
28. Choyke PL: Pilot study of FPPRGD2 for imaging alpha(v)beta(3) integrin - how integral are integrins?. Radiology 2011;260:1-2
29. Beer AJ, Lorenzen S, Metz S, et al: Comparison of integrin alphaVbeta3 expression and glucose metabolism in primary and metastatic lesions in cancer patients: A PET study using 18F-galacto-RGD and 18F-FDG. J Nucl Med 2008;49:22-29
30. Kenny LM, Coombes RC, Oulie I, et al: Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients. J Nucl Med 2008;49:879-886 (Pubitemid 351793427)
31. Virgolini I, Ambrosini V, Bomanji JB, et al: Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging 2010;37:2004-2010
32. Kayani I, Conry BG, Groves AM, et al: A comparison of 68Ga-DOTATATE and 18F-FDG-PET/CT in pulmonary neuroendocrine tumors. J Nucl Med 2009;50(12):1927-1932
33. Ambrosini V, Tomassetti P, Castellucci P, et al: Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging 2008;35:1431-1438